Regeneron Pharmaceuticals, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Leonard S. Schleifer
- Full Time Employees
- 15,410
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 777 Old Saw Mill River Road Tarrytown NY United States 10591-6707
- IPO Date
- Apr 2, 1991
- CIK
- 0000872589
- Website
- regeneron.com
- Similar Companies
- Business
- Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases including eye disorders, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases. Founded in 1988 and headquartered in Tarrytown, New York, the company operates globally with facilities in the United States and clinical trials underway in more than 50 countries; it employs proprietary technologies such as VelociSuite for fully human antibodies and bispecifics, Trap fusion proteins and the Regeneron Genetics Center for data-powered insights. Its marketed products include EYLEA (aflibercept) for retinal diseases such as wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion; Dupixent (dupilumab, in collaboration with Sanofi) for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and other allergic conditions; Praluent (alirocumab) for hypercholesterolemia; Kevzara (sarilumab, with Sanofi) for rheumatoid arthritis; Libtayo (cemiplimab) for cutaneous squamous cell carcinoma and other cancers; ARCALYST (rilonacept) for autoinflammatory diseases; ZALTRAP (ziv-aflibercept) for metastatic colorectal cancer; Inmazeb for Ebola virus infection; Veopoz (pozelimab) for CHAPLE disease; as well as investigational candidates across oncology, hematology, immunology and neurology. In recent developments, Regeneron formed Regeneron Cell Medicines in 2024 through an agreement acquiring 2seventy bio's immune cell therapy pipeline, discovery and manufacturing capabilities along with approximately 150 employees in Cambridge, Massachusetts, and Seattle, Washington; announced a $3 billion-plus, 10-year manufacturing agreement with FUJIFILM Diosynth Biotechnologies in 2025 to nearly double U.S. large-scale capacity at the Holly Springs, North Carolina facility; launched a $500 million venture capital fund in 2024 focused on biotech investments; entered a collaboration with Tessera Therapeutics in December 2025 to co-develop TSRA-196, a gene-editing therapy for alpha-1 antitrypsin deficiency, with Tessera receiving $150 million upfront and up to $125 million in milestones; secured FDA approval for EYLEA HD in retinal vein occlusion with expanded dosing in 2025; and won a $406.8 million antitrust judgment against Amgen in May 2025 over Praluent market exclusion. The company continues to advance its pipeline with positive late-stage data in immunology, allergy, neurology and rare diseases, while expanding R&D investments and domestic manufacturing to support growth.
Company News
Regeneron Pharmaceuticals, Inc. $REGN Stock: AIA Group Ltd Decreases Holdings
Regeneron Pharmaceuticals, Inc. $REGN Stock: Bank Julius Baer & Co. Ltd Zurich Raises Stake
Why Regeneron (REGN) Might be Well Poised for a Surge
REGN vs. ILMN: Which Stock Is the Better Value Option?
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades'
3,572 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by International Assets Investment Management LLC
Regeneron Announces Investor Conference Presentations
These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Critical Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron: 3 Key Takeaways for Long-Term Investors
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Regeneron Is Just Getting Started
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
Regeneron Reports Third Quarter 2026 Financial and Operating Results